Sponsored Content

Articles by Sponsored Content

POLIVY + BR: A Therapeutic Option Granted Accelerated Approval for R/R 3/L+DLBCL, NOS

BySponsored Content

February 2nd 2020

The Proposed Mechanism of Action of POLIVY for R/R DLBCL, NOS

BySponsored Content

February 1st 2020

Vincent Herrin, MD - University of Mississippi Medical Center Jackson, Mississippi

Latest Updated Articles

POLIVY + BR: A Therapeutic Option Granted Accelerated Approval for R/R 3/L+DLBCL, NOS
February 2nd 2020
The Proposed Mechanism of Action of POLIVY for R/R DLBCL, NOS
February 1st 2020

Trending on Targeted Onc

DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC

Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL

FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors

FDA Grants RMAT and Fast Track Status to Prizlon-Cel in R/R LBCL

Phase 3 Results Point to a Path Forward for Cancer Vaccines